AstraZeneca vaccines meant for and paid for by the EU could have ended up in Britain, diplomatic sources in Brussels claimed today. The suspicion is that the British-Swedish pharmaceutical company supplied the UK from the EU vaccine stock because Britain paid a higher price for the dose and approved it sooner. On Monday, Brussels threatened to block EU vaccine exports to non-EU countries, after AstraZeneca revealed that it would not be able to fulfil its contractual obligations as originally hoped. Ursula von der Leyen, the European Commission president, said on Tuesday that the EU would press on with the export mechanism that would force companies to ask for permission before vaccines could leave the bloc. In a speech to the World Economic Forum in Davos, Mrs von der Leyen said, “Europe invested billions to help develop the world’s first Covid-19 vaccines to create a truly global common good. Europe is determined to contribute to this global common good but it also means business.” She added: “And now, the companies must deliver. They must honour their obligations and this is why we will set up a vaccine export to transparency mechanism.” A European Commission spokesman said: “How worried are we about the state of vaccinations? Well, we are worried that is for sure. We are dealing with a very important pandemic and vaccination is very important.” The UK is dependent on the Pfizer vaccine, which is produced in Belgium, and is expecting almost 3.5million doses to be delivered in the next three weeks. That supply could be jeopardised if the EU decided to block the exports after the AstraZeneca controversy.